Oncoinvent ASA (CHIX:ONCINO) Net Interest Margin (Bank Only) %


CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr19,149.99
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 94.6% below its estimated GF Value™ of kr19,149.99.

Key valuation signals for CHIX:ONCINO:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr19,149.99 vs. price of kr1,039.91 (94.6% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr19,149.99
GF Value